Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence
Richard A. Larson(Urbana University), Matthias Theobald(Johannes Gutenberg University Mainz), Jacques J. M. van Dongen(Universidad de Salamanca), Edward A. Stadtmauer(University of Pennsylvania), Eric L. Sievers(Seagen (United States)), D. Voliotis(Bayer (United States)), Bob Löwenberg(Unknown), Irwin D. Bernstein(Fred Hutch Cancer Center), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Maria Richie(Employment Agency), Elihu H. Estey(University of Washington), Michael R. Loken(Unknown), John M. Bennett(University of Rochester Medical Center), Matthew L. Sherman, Lance Leopold(Employment Agency), Hervé Dombret(University of London Institute in Paris), Mark S. Berger(Erasmus MC Cancer Institute)
Cited by 459